update, page-55

Jonty

I think it will be big, as the oral-care sector is a multi-billion dollar expanding glabal market that doesn't have the regulatory grief drug development brings.

An anecdotal example - Every month when I look in the toothpaste asle in the supermarket, there allways seems to be a trusted brand of toothpaste (ie- macleans, seredyne, colgate) announcing a a new ingredient/improvement - such as:

"new added germ fighters/whiteners/anti-plague agents, etc.

This market is big bucks and OBJ is in a position to give GSK a marketing edge - plus, of course, real product improvement (which OBJ is currently in the process of developing for GSK).

That's why I'm happy with the GSK part of the announcement.